Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Doximity Inc(DOCS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DOCS
09/25/2026: DOCS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Doximity is a digital platform and professional network designed specifically for US physicians, providing communication, telehealth, and workflow tools. The company benefits from high user trust and a sticky, high-margin software model that supports its primary pharmaceutical marketing business. Its main growth story centers on increasing platform utility through AI productivity tools and expanding enterprise subscription services to health systems. Key risks include heavy reliance on pharmaceutical advertising budgets and potential competition from larger tech platforms. The company is best suited for growth-oriented investors looking for exposure to digital healthcare, though investors should monitor advertising budget trends and regulatory developments carefully.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Doximity offers a scalable software model targeting high-value professional markets. |
| Momentum investor | Mixed fit | The stock often follows broader tech and health-tech sentiment trends. |
| Value investor | Weak fit | Valuation multiples often command a growth premium consistent with tech software firms. |
| Dividend investor | Weak fit | The company does not pay a dividend, focusing entirely on growth reinvestment. |
| Low-risk investor | Weak fit | The stock exhibits volatility typical of mid-cap growth and software technology equities. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Technology-focused stocks often experience significant price swings based on macro sentiment. |
| Valuation risk | Medium | Investors pay a premium for growth, which can contract if revenue acceleration slows. |
| Competition risk (advertising and AI) | Medium | Increasing competition from both established players and new AI-driven health startups could pressure margins. |
| Business quality | Strong | The company benefits from a high-margin, sticky, and network-effect-driven business model. |
| Dividend income | Low / none | Investors cannot rely on the stock for consistent income generation. |
| Execution risk | Medium | The company must successfully innovate to maintain its relevance in an evolving digital healthcare landscape. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 8.49% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.64B USD | Price to earnings Ratio 31 | 1Y Target Price 29.94 |
Price to earnings Ratio 31 | 1Y Target Price 29.94 | ||
Volume (30-day avg) 2.8M shares | Beta 1.25 | 52 Weeks Range 17.15 - 76.51 | Updated Date 09/25/2026 |
52 Weeks Range 17.15 - 76.51 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.84 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Subscription Services | Fees from health systems for enterprise-grade telehealth and workflow products. | Steady recurring revenue from hospitals and health systems. |
| Marketing Solutions | Advertising revenue from pharmaceutical companies seeking to reach physicians. | Primary driver of growth, dependent on pharmaceutical marketing budgets. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 31 | Forward PE 19.76 | Enterprise Value 4.06B | Price to Sales(TTM) 7.08 |
Enterprise Value 4.06B | Price to Sales(TTM) 7.08 | ||
Enterprise Value to Revenue 6.19 | Enterprise Value to EBITDA 19.33 | Shares Outstanding 127.35M | Shares Floating 123.64M |
Shares Outstanding 127.35M | Shares Floating 123.64M | ||
Percent Insiders 2.86 | Percent Institutions 102.95 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Doximity Inc
Exchange NYSE | Headquarters San Francisco, CA, United States | ||
IPO Launch date 2021-06-24 | Co-Founder, CEO & Chairperson Mr. Jeffrey A. Tangney | ||
Sector Healthcare | Industry Health Information Services | Full time employees 880 | Website https://www.doximity.com |
Full time employees 880 | Website https://www.doximity.com | ||
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.